These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 19740399

  • 21. Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients.
    Kuypers DR, Naesens M, de Jonge H, Lerut E, Verbeke K, Vanrenterghem Y.
    Ther Drug Monit; 2010 Aug; 32(4):394-404. PubMed ID: 20526235
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Association of CYP3A polymorphisms with the pharmacokinetics of cyclosporine A in early post-renal transplant recipients in China.
    Meng XG, Guo CX, Feng GQ, Zhao YC, Zhou BT, Han JL, Chen X, Shi Y, Shi HY, Yin JY, Peng XD, Pei Q, Zhang W, Wang G, He M, Liu M, Yang JK, Zhou HH.
    Acta Pharmacol Sin; 2012 Dec; 33(12):1563-70. PubMed ID: 23085740
    [Abstract] [Full Text] [Related]

  • 25. Impact of ATP-binding cassette, subfamily B, member 1 pharmacogenetics on tacrolimus-associated nephrotoxicity and dosage requirements in paediatric patients with liver transplant.
    Hawwa AF, McElnay JC.
    Expert Opin Drug Saf; 2011 Jan; 10(1):9-22. PubMed ID: 20629603
    [Abstract] [Full Text] [Related]

  • 26. Personalized tacrolimus doses determined by CYP3A5 genotype for induction and maintenance phases of kidney transplantation.
    Vannaprasaht S, Reungjui S, Supanya D, Sirivongs D, Pongskul C, Avihingsanon Y, Tassaneeyakul W.
    Clin Ther; 2013 Nov; 35(11):1762-9. PubMed ID: 24120259
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. The Impact of ABCB1 SNPs on Tacrolimus Pharmacokinetics in Liver or Kidney Transplant Recipients: A Meta-analysis.
    Li Z, Wang X, Li D, Cheng S, Dong Y, Yang H, Li X.
    Curr Pharm Des; 2023 Nov; 29(29):2323-2335. PubMed ID: 37817654
    [Abstract] [Full Text] [Related]

  • 29. Association of CYP3A5, CYP2C8, and ABCB1 Polymorphisms With Early Renal Injury in Chinese Liver Transplant Recipients Receiving Tacrolimus.
    Deng R, Liao Y, Li Y, Tang J.
    Transplant Proc; 2018 Dec; 50(10):3258-3265. PubMed ID: 30577195
    [Abstract] [Full Text] [Related]

  • 30. CYP3A5 and ABCB1 polymorphisms in living donors do not impact clinical outcome after kidney transplantation.
    Yang L, de Winter BC, van Schaik RH, Xie RX, Li Y, Andrews LM, Shuker N, Bahmany S, Koch B, van Gelder T, Hesselink DA.
    Pharmacogenomics; 2018 Jul 01; 19(11):895-903. PubMed ID: 29991328
    [Abstract] [Full Text] [Related]

  • 31. 1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation.
    Elens L, Capron A, Kerckhove VV, Lerut J, Mourad M, Lison D, Wallemacq P, Haufroid V.
    Pharmacogenet Genomics; 2007 Oct 01; 17(10):873-83. PubMed ID: 17885626
    [Abstract] [Full Text] [Related]

  • 32. Impact of Pharmacogenetic Determinants of Tacrolimus and Mycophenolate on Adverse Events in Renal Transplant Patients.
    Thishya K, Sreenu B, Raju SB, Kutala VK.
    Curr Drug Metab; 2021 Oct 01; 22(5):342-352. PubMed ID: 33459227
    [Abstract] [Full Text] [Related]

  • 33. Effect of CYP3A5, CYP3A4, and ABCB1 genotypes as determinants of tacrolimus dose and clinical outcomes after heart transplantation.
    Díaz-Molina B, Tavira B, Lambert JL, Bernardo MJ, Alvarez V, Coto E.
    Transplant Proc; 2012 Nov 01; 44(9):2635-8. PubMed ID: 23146479
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Associations of ABCB1 3435C>T and IL-10-1082G>A polymorphisms with long-term sirolimus dose requirements in renal transplant patients.
    Sam WJ, Chamberlain CE, Lee SJ, Goldstein JA, Hale DA, Mannon RB, Kirk AD, Hon YY.
    Transplantation; 2011 Dec 27; 92(12):1342-7. PubMed ID: 22094953
    [Abstract] [Full Text] [Related]

  • 38. Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids.
    Mourad M, Mourad G, Wallemacq P, Garrigue V, Van Bellingen C, Van Kerckhove V, De Meyer M, Malaise J, Eddour DC, Lison D, Squifflet JP, Haufroid V.
    Transplantation; 2005 Oct 15; 80(7):977-84. PubMed ID: 16249748
    [Abstract] [Full Text] [Related]

  • 39. Association of MDR1 gene SNPs and haplotypes with the tacrolimus dose requirements in Han Chinese liver transplant recipients.
    Yu X, Xie H, Wei B, Zhang M, Wang W, Wu J, Yan S, Zheng S, Zhou L.
    PLoS One; 2011 Oct 15; 6(11):e25933. PubMed ID: 22110582
    [Abstract] [Full Text] [Related]

  • 40. Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation.
    Gervasini G, Garcia M, Macias RM, Cubero JJ, Caravaca F, Benitez J.
    Transpl Int; 2012 Apr 15; 25(4):471-80. PubMed ID: 22369694
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.